查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965778

軟組織肉瘤市場－全球產業規模、佔有率、趨勢、機會、預測：按治療類型、最終用戶、地區和競爭對手分類，2021-2031年

Soft Tissue Sarcoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球軟組織肉瘤市場預計將從 2025 年的 17.1 億美元成長到 2031 年的 27.8 億美元，複合年成長率為 8.44%。

軟組織肉瘤是指一群罕見的惡性腫瘤，這些腫瘤發生於脂肪、肌肉、神經和血管等結締組織。全球軟組織肉瘤市場的成長主要受此類疾病發生率上升以及免疫療法和標靶藥物等創新治療方法快速發展所驅動，這些療法與傳統化療相比，能顯著改善患者的預後。為了凸顯疾病的流行程度，美國癌症協會預測，到2025年，美國將新增約13,520例軟組織肉瘤病例。

市場概覽
預測期 2027-2031
市場規模：2025年 17.1億美元
市場規模：2031年 27.8億美元
複合年成長率：2026-2031年 8.44%
成長最快的細分市場 抗血管新生藥物
最大的市場 北美洲

儘管取得了這些進展，但尖端生物療法的高成本仍然是市場發展的重要障礙。各地區嚴格的報銷政策進一步加劇了這一沉重的經濟負擔，限制了患者獲得救命藥物的機會，也限制了生產商的產生收入。因此，治療費用仍然是一個主要挑戰，嚴重限制了有效治療方法的推廣，並可能阻礙全球軟組織肉瘤市場的整體成長。

市場促進因素

免疫療法和標靶治療的快速發展正在改變軟組織肉瘤的治療標準，使其不再局限於傳統化療，從根本上改變了全球軟組織肉瘤市場。美國食品藥物管理局 (FDA) 加速核准Tessella（afamitresgen autoleucel）用於治療滑膜肉瘤，這標誌著一個重要的里程碑，因為它是第一個針對固態腫瘤設計的基因修飾細胞療法。這項創新滿足了具有特定基因譜的患者的巨大未滿足需求，為傳統治療方法失效的領域帶來了新的希望。 Adaptive Immune Therapeutics 公司於 2024 年 8 月公佈的 SPEARHEAD-1 試驗數據顯示，在多重抗藥性患者中，總緩解率達到 43.2%，顯著超過了以往的基準值。這些突破性成果的商業性潛力顯而易見。 2024 年 8 月， 自我調整 Immune Therapeutics 預測，其肉瘤治療業務在美國的年銷售額尖峰時段可達約 4 億美元，凸顯了腫瘤學這一細分領域的盈利商機。

同時，全球軟組織肉瘤發生率和盛行率的上升是推動市場擴張的主要動力。隨著人口老化和診斷能力的提高，這些罕見惡性腫瘤的負擔正在穩步加重，亟需更廣泛地獲得有效治療，並催生對新療法的迫切需求。根據2024年5月發表於《柳葉刀》的“2021年全球疾病負擔研究”，2021年全球軟組織和骨外肉瘤的年發病率達到96,201例，反映了過去30年來疾病負擔的持續累積。患者數量的增加將促使製藥公司加快臨床開發平臺，並鼓勵醫療系統將更多資源投入肉瘤專科治療中，從而推動市場長期持續成長。

市場挑戰

先進治療性介入帶來的巨大經濟負擔是限制全球軟組織肉瘤市場成長的主要因素。生物製藥和標靶治療的高昂採集費用往往超出公共和私人保險公司設定的報銷限額。這種定價結構導致嚴格的報銷通訊協定和拒付情況，使得相當一部分患者無法獲得必要的治療。根據美國國家癌症研究所預測，到2024年，軟組織肉瘤的5年存活率為65.8%。

儘管這項生存指標凸顯了持續獲得有效治療的迫切性，但經濟障礙卻嚴重阻礙了這種獲取。當患者因經濟負擔（經濟毒性）而放棄治療或選擇療效較差的替代方案時，昂貴治療方法的市場滲透率將受到嚴重限制。因此，臨床可近性與患者支付能力之間的差距限制了製造商的投資回報，進而影響了全球市場的整體獲利能力和商業性擴張。

市場趨勢

將人工智慧 (AI) 應用於肉瘤診斷正成為一種變革性趨勢，旨在應對組織學異質性這一重大挑戰，因為組織學異質性會嚴重影響準確診斷。先進的演算法正被用於分析電腦斷層掃描的放射組學數據，從而實現更精確的腫瘤分級和亞型分類，而無需立即進行侵入性操作。這項技術突破透過促進更早、更準確的干涉並降低誤診率，直接影響患者管理策略。正如 2024 年 1 月 RAD 雜誌一篇題為「研究表明，人工智慧比切片檢查更能準確地幫助制定罕見肉瘤的個人化治療方案」的報導中所述，新開發的 AI 演算法在所檢查的肉瘤中準確預測了 84% 的疾病類型，在區分複雜亞型方面顯著優於標準切片檢查方法。

同時，市場正在策略性地轉向採用液態生物檢體和循環腫瘤DNA（ctDNA）分析，以克服傳統組織取樣在監測疾病進展方面的限制。這種非侵入性方法能夠即時檢測分子層面的殘留病灶，並識別可治療的基因組突變，這對於沒有復發性驅動突變的亞型尤其重要。根據2024年5月在美國臨床腫瘤學會（ASCO）上發表的一篇題為“多重檢測液態生物檢體方法提高骨和軟組織肉瘤的檢測準確性”的摘要，在診斷時融合基因陰性的橫紋肌肉瘤樣本中，100%的樣本均成功檢測到了循環腫瘤物質，證實了該方法在追蹤難以檢測的惡性腫瘤方面的高靈敏度。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球軟組織肉瘤市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（標靶治療、化療、抗血管新生藥物、放射線治療、其他）
    • 依最終使用者（醫院、居家醫療、專科醫療中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美軟組織肉瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲軟組織肉瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區軟組織肉瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲軟組織肉瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲軟組織肉瘤市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球軟組織肉瘤市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd.
  • Viatris Inc
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17108

The Global Soft Tissue Sarcoma Market is projected to expand from a valuation of USD 1.71 Billion in 2025 to USD 2.78 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 8.44%. Soft tissue sarcomas represent a diverse collection of rare malignancies that originate in connective tissues, including fat, muscle, nerves, and blood vessels. The growth of this global market is largely propelled by the increasing incidence of these conditions and the rapid advancement of innovative therapeutic modalities, such as immunotherapies and targeted drugs, which provide superior patient outcomes compared to conventional chemotherapy. Highlighting the prevalence of the disease, the American Cancer Society projected that approximately 13,520 new cases of soft tissue sarcoma would be diagnosed in the United States in 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.71 Billion
Market Size 2031USD 2.78 Billion
CAGR 2026-20318.44%
Fastest Growing SegmentAnti-angiogenesis Drugs
Largest MarketNorth America

Despite these advancements, the market faces a substantial obstacle due to the high costs associated with cutting-edge biologic therapies. This significant financial burden, exacerbated by strict reimbursement policies in various regions, restricts patient access to essential life-saving medications and constrains revenue generation for manufacturers. Consequently, affordability remains a critical challenge that could severely limit the broader adoption of effective treatments and hinder the overall expansion of the global soft tissue sarcoma market.

Market Driver

Rapid progress in immunologics and targeted therapies is fundamentally transforming the global soft tissue sarcoma market, shifting treatment standards beyond traditional chemotherapy. A major milestone was achieved with the FDA's accelerated approval of Tecelra (afamitresgene autoleucel) for synovial sarcoma, representing the first engineered cell therapy designed for a solid tumor. This innovation meets significant unmet needs for patients with specific genetic profiles, offering new hope where conventional options have failed. Data from Adaptimmune Therapeutics in August 2024 regarding the 'SPEARHEAD-1' trial indicated an overall response rate of 43.2% among heavily pre-treated patients, significantly outperforming historical benchmarks. The commercial potential of such breakthroughs is evident, with Adaptimmune Therapeutics projecting in August 2024 that its sarcoma franchise could generate approximately $400 million in peak annual sales in the United States, underscoring the lucrative opportunities in this niche oncology sector.

Concurrently, the rising global incidence and prevalence of soft tissue sarcomas act as a primary catalyst for market expansion. As populations age and diagnostic capabilities improve, the identified burden of these rare malignancies continues to increase, necessitating wider access to effective treatments and driving demand for novel therapeutics. According to the Global Burden of Disease Study 2021, published in The Lancet in May 2024, the global annual incidence of soft tissue and extraosseous sarcomas reached 96,201 cases in 2021, reflecting a consistent accumulation of disease burden over the past three decades. This growing patient population compels pharmaceutical developers to accelerate their clinical pipelines and encourages healthcare systems to allocate greater resources toward specialized sarcoma care, thereby sustaining long-term market growth.

Market Challenge

The substantial financial pressure associated with advanced therapeutic interventions constitutes a primary restraint on the growth of the global soft tissue sarcoma market. High acquisition costs for biologic agents and targeted therapies often exceed the coverage limits set by public and private payers. This pricing structure frequently results in strict reimbursement protocols or coverage denials, effectively preventing a significant portion of the patient population from accessing necessary care. According to the National Cancer Institute, the 5-year relative survival rate for soft tissue sarcoma was reported to be 65.8 percent in 2024.

This survival metric highlights the urgent need for consistent access to effective therapies, yet economic barriers significantly disrupt this access. When financial toxicity forces patients to forego treatment or settle for less effective alternatives, the market penetration of premium therapies is severely curtailed. Consequently, the disparity between clinical availability and patient affordability restricts the return on investment for manufacturers, thereby limiting the overall revenue potential and commercial expansion of the global market.

Market Trends

The integration of Artificial Intelligence (AI) into sarcoma diagnostics is emerging as a transformative trend, addressing the critical challenge of histological heterogeneity that often complicates accurate diagnosis. Advanced algorithms are now utilized to analyze radiomic data from CT scans, enabling more precise tumor grading and subtype classification without the immediate need for invasive procedures. This technological leap facilitates earlier and more accurate interventions, directly influencing patient management strategies by reducing misdiagnosis rates. As noted by RAD Magazine in January 2024, in an article titled 'Research shows AI helps tailor treatment for rare sarcomas more accurately than biopsy,' a newly developed AI algorithm accurately predicted the disease type of 84% of tested sarcomas, significantly outperforming the diagnostic accuracy of standard biopsy methods in differentiating between complex subtypes.

Simultaneously, the market is witnessing a strategic shift toward the adoption of liquid biopsy and circulating tumor DNA (ctDNA) analysis to overcome the limitations of traditional tissue sampling in monitoring disease progression. This non-invasive modality allows for the real-time detection of molecular residual disease and the identification of actionable genomic alterations, which is particularly vital for subtypes that lack recurrent driver mutations. According to an abstract from the American Society of Clinical Oncology in May 2024 titled 'A multi-assay liquid biopsy approach to improve detection of bone and soft tissue sarcomas,' circulating tumor material was successfully detected in 100% of fusion-negative rhabdomyosarcoma samples at the time of diagnosis, underscoring the high sensitivity of this approach for tracking hard-to-detect malignancies.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Viatris Inc
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

Report Scope

In this report, the Global Soft Tissue Sarcoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Soft Tissue Sarcoma Market, By Treatment Type

  • Targeted Therapy
  • Chemotherapy
  • Anti-Angiogenesis Drugs
  • Radiation Therapy
  • Others

Soft Tissue Sarcoma Market, By End User

  • Hospitals
  • Homecare
  • Specialty Centers
  • Others

Soft Tissue Sarcoma Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Soft Tissue Sarcoma Market.

Available Customizations:

Global Soft Tissue Sarcoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Soft Tissue Sarcoma Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others)
    • 5.2.2. By End User (Hospitals, Homecare, Specialty Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Soft Tissue Sarcoma Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Soft Tissue Sarcoma Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Soft Tissue Sarcoma Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Soft Tissue Sarcoma Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End User

7. Europe Soft Tissue Sarcoma Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Soft Tissue Sarcoma Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Soft Tissue Sarcoma Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Soft Tissue Sarcoma Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Soft Tissue Sarcoma Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Soft Tissue Sarcoma Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Soft Tissue Sarcoma Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Soft Tissue Sarcoma Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Soft Tissue Sarcoma Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Soft Tissue Sarcoma Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Soft Tissue Sarcoma Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Soft Tissue Sarcoma Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Soft Tissue Sarcoma Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Soft Tissue Sarcoma Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Soft Tissue Sarcoma Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Soft Tissue Sarcoma Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End User

10. South America Soft Tissue Sarcoma Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Soft Tissue Sarcoma Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Soft Tissue Sarcoma Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Soft Tissue Sarcoma Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Soft Tissue Sarcoma Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Viatris Inc
  • 15.3. Teva Pharmaceutical Industries Ltd.
  • 15.4. Sanofi
  • 15.5. Pfizer Inc.
  • 15.6. GSK plc
  • 15.7. Novartis AG
  • 15.8. Bayer AG
  • 15.9. Sun Pharmaceutical Industries Ltd.
  • 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer